Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab.

The Kaplan–Meier analysis showed a trend toward improved OS among patients with high STING-expressing tumors, with a median OS of 74.7 months versus 25.4 months in the high- and low-expression groups, respectively, although this difference was not statistically significant (log-rank P = 0.06; Supplementary Figure S6 , available at https://doi.org/10.1016/j.esmoop.2026.106908 ).

also in 53,322 other papers